Historical Context

Understanding the legal intricacies of CBD requires a look into its history. CBD is one of many cannabinoids in the cannabis plant, distinct from THC (tetrahydrocannabinol), the psychoactive compound in marijuana. The legal classification of cannabis, including CBD, has changed over time due to shifting societal attitudes, scientific research, and legislative decisions.

In 1970, the Controlled Substances Act labeled cannabis as a Schedule I controlled substance, hindering research on cannabinoids. The turning point came with the 2014 Farm Bill, which differentiated between hemp and marijuana. Hemp, with less than 0.3% THC, became legal for cultivation and research. The 2018 Farm Bill expanded this, removing hemp-derived CBD from Schedule I status and allowing widespread production.

Collapsible content

Legalization and Regulation

While the 2018 Farm Bill legalized hemp-derived CBD federally, its regulation remains complex. The Food and Drug Administration (FDA) oversees CBD in food, supplements, and cosmetics. As of my last knowledge update in January 2022, the FDA hasn't approved CBD as a food additive or supplement due to safety concerns and the lack of standardized dosing.

State-by-State Variances

CBD's legal status varies across states. Some fully embrace it, aligning with federal laws, while others impose restrictions or maintain strict prohibitions. This state-by-state patchwork creates challenges for businesses and consumers navigating the market.

International Perspectives

Globally, CBD's legality differs. Some countries embrace it, while others classify it as a controlled substance. The EU, for example, allows CBD with conditions under its Novel Food Regulation, demonstrating ongoing efforts to establish international regulations.

Challenges and Concerns

The evolving legal status of CBD presents challenges. Inconsistent testing and labeling practices in the industry lead to varied product quality and inaccurate potency claims. The FDA's cautious stance on CBD as a food or supplement ingredient creates uncertainty, contributing to the proliferation of unregulated products.


CBD's journey from prohibition to mainstream wellness products is marked by legal complexities. The 2018 Farm Bill was a milestone, but challenges persist, such as state variations, international differences, and concerns about product quality. As regulations continue to develop, staying informed is crucial for consumers and businesses navigating the evolving legal landscape. Balancing the potential benefits of CBD with public health considerations remains a delicate task for legislators and regulators.

  • Manufactured in the USA

    All CleanAF CBD products are filled, assembled and packaged at our manufacturing facility in Clearwater, FL.

    See FAQs 
  • Independently Lab Tested

    All of our products are third-party lab tested to ensure everything you use that bears our name is accurately labeled and safe to use.

    View Lab Results 
  • Quality Guaranteed

    Every CleanAF CBD product comes with a 100% Quality Guarantee. If you ever run into issues - Please let us know!

    Read More 
1 of 3

FDA Stance on CBD

As of my last knowledge update in January 2022, the U.S. Food and Drug Administration (FDA) has been actively evaluating the regulatory status of CBD (cannabidiol) products. The FDA's stance on CBD has evolved over time, and several key points can be highlighted:

FDA Approval - The FDA has approved a prescription medication called Epidiolex, which contains purified CBD, for the treatment of seizures associated with certain rare forms of epilepsy. This approval signifies the acknowledgment of CBD as a therapeutic substance under specific medical conditions.

Concerns about Unsubstantiated Health Claims - The FDA has expressed concerns about the marketing of CBD products with unproven health claims. The agency has emphasized the importance of conducting rigorous scientific research to support the safety and efficacy of CBD in various uses.

Regulatory Uncertainty - The regulatory framework for non-prescription CBD products, including dietary supplements and food products, has been less clear. The FDA has worked to gather information and conduct studies to address safety concerns, potential adverse effects, and appropriate regulatory pathways.

Enforcement Actions - The FDA has taken enforcement actions against companies making exaggerated health claims or selling CBD products that do not meet regulatory standards. This includes warning letters to companies violating FDA regulations.

It's important to note that regulatory developments may have occurred since my last update, and the FDA's stance on CBD may have evolved. Individuals should check the FDA's official website or other reliable sources for the latest information on CBD regulations and the FDA's position.